CoChat

Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer

Open access
Johansson, Henrik J., Sanchez, Betzabe C., Mundt, Filip, Forshed, Jenny, Kovacs, Aniko, Panizza, Elena, Hultin-Rosenberg, Lina, Lundgren, Bo, Martens, Ulf, Máthé, Gyöngyvér, Yakhini, Zohar, Helou, Khalil, Krawiec, Kamilla, Kanter, Lena, Hjerpe, Anders, Stål, Olle, Linderholm, Barbro K., Lehtiö, Janne · 2013 · Nature Communications
Cited by 60

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

About one-third of oestrogen receptor alpha-positive breast cancer patients treated with tamoxifen relapse. Here we identify the nuclear receptor retinoic acid receptor alpha as a marker of tamoxifen resistance. Using quantitative mass spectrometry-based proteomics, we show that retinoic acid receptor alpha protein networks and levels differ in a tamoxifen-sensitive (MCF7) and a tamoxifen-resistant (LCC2) cell line. High intratumoural retinoic acid receptor alpha protein levels also correlate with reduced relapse-free survival in oestrogen receptor alpha-positive breast cancer patients treated with adjuvant tamoxifen solely. A similar retinoic acid receptor alpha expression pattern is seen in a comparable independent patient cohort. An oestrogen receptor alpha and retinoic acid receptor alpha ligand screening reveals that tamoxifen-resistant LCC2 cells have increased sensitivity to retinoic acid receptor alpha ligands and are less sensitive to oestrogen receptor alpha ligands compared with MCF7 cells. Our data indicate that retinoic acid receptor alpha may be a novel therapeutic target and a predictive factor for oestrogen receptor alpha-positive breast cancer patients treated with adjuvant tamoxifen. Many patients with breast cancer develop resistance to the drug tamoxifen and relapse. Here Johansson et al. identify the nuclear receptor retinoic acid receptor alpha (RARA) as a marker of tamoxifen resistance and show that RARA expression correlates negatively with relapse-free survival of patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms3175

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 40

  1. Colditz, G. A. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J. Natl. Cancer Inst. 90, 814–823 (1998). · DOI · Paper page
  2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005). · DOI · Paper page
  3. Musgrove, E. A. & Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631–643 (2009). · DOI · Paper page
  4. Michalides, R. et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 5, 597–605 (2004). · DOI · Paper page
  5. van Agthoven, T. et al. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J. Clin. Oncol. 27, 542–549 (2009). · DOI · Paper page
  6. van Agthoven, T. et al. Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res. Treat. 114, 23–30 (2009). · DOI
  7. van Agthoven, T., Godinho, M. F., Wulfkuhle, J. D., Petricoin, E. F. 3rd & Dorssers, L. C. Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines. Int. J. Cancer 131, 1998–2007 (2012). · DOI
  8. Linderholm, B. et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J. Clin. Oncol. 18, 1423–1431 (2000). · DOI · Paper page
  9. Linderholm, B. K. et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res. 61, 2256–2260 (2001).
  10. Aesoy, R. et al. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol. Cancer Res. 6, 1630–1638 (2008). · DOI
  11. Hua, S., Kittler, R. & White, K. P. Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 137, 1259–1271 (2009). · DOI · Paper page
  12. Ross-Innes, C. S. et al. Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev. 24, 171–182 (2010). · DOI · Paper page
  13. Altucci, L., Leibowitz, M. D., Ogilvie, K. M., de Lera, A. R. & Gronemeyer, H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug. Discov. 6, 793–810 (2007). · DOI · Paper page
  14. Decensi, A. et al. Randomized double-blind 2 × 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J. Clin. Oncol. 27, 3749–3756 (2009). · DOI
  15. Gonzalez-Angulo, A. M., Hennessy, B. T. & Mills, G. B. Future of personalized medicine in oncology: a systems biology approach. J. Clin. Oncol. 28, 2777–2783 (2010). · DOI · Paper page
  16. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869–10874 (2001). · DOI · Paper page
  17. Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790–800 (2009). · DOI · Paper page
  18. Symmans, W. F. et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J. Clin. Oncol. 28, 4111–4119 (2010). · DOI · Paper page
  19. Altelaar, A. F., Munoz, J. & Heck, A. J. Next-generation proteomics: towards an integrative view of proteome dynamics. Nat. Rev. Genet. 14, 35–48 (2013). · DOI · Paper page
  20. Brunner, N. et al. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res. 53, 3229–3232 (1993).
  21. Linderholm, B., Lindh, B., Tavelin, B., Grankvist, K. & Henriksson, R. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int. J. Cancer 89, 51–62 (2000). · DOI · Paper page
  22. Hua, S. et al. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol. Syst. Biol. 4, 188 (2008). · DOI · Paper page
  23. Saito, A. et al. All-trans retinoic acid induces in vitro angiogenesis via retinoic acid receptor: possible involvement of paracrine effects of endogenous vascular endothelial growth factor signaling. Endocrinology 148, 1412–1423 (2007). · DOI · Paper page
  24. Godinho, M. F. et al. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. Br. J. Cancer 107, 947–955 (2012). · DOI
  25. Lim, J. S., Park, S. H. & Jang, K. L. All-trans retinoic acid induces cellular senescence by up-regulating levels of p16 and p21 via promoter hypomethylation. Biochem. Biophys. Res. Commun. 412, 500–505 (2011). · DOI
  26. Park, S. H., Lim, J. S. & Jang, K. L. All-trans retinoic acid induces cellular senescence via upregulation of p16, p21, and p27. Cancer Lett. 310, 232–239 (2011). · DOI
  27. Lonard, D. M. & O'Malley, B. W. The expanding cosmos of nuclear receptor coactivators. Cell 125, 411–414 (2006). · DOI · Paper page
  28. Tanaka, T., Rodriguez de la Concepcion, M. L. & De Luca, L. M. Involvement of all-trans-retinoic acid in the breakdown of retinoic acid receptors alpha and gamma through proteasomes in MCF-7 human breast cancer cells. Biochem. Pharmacol. 61, 1347–1355 (2001). · DOI
  29. Laursen, K. B., Wong, P. M. & Gudas, L. J. Epigenetic regulation by RARalpha maintains ligand-independent transcriptional activity. Nucleic. Acids. Res. 40, 102–115 (2012). · DOI
  30. Hurtado, A. et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456, 663–666 (2008). · DOI · Paper page
  31. Germain, P. et al. Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists. Chem. Biol. 16, 479–489 (2009). · DOI
  32. Lu, Y., Bertran, S., Samuels, T. A., Mira-y-Lopez, R. & Farias, E. F. Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARalpha agonist AM580. Oncogene 29, 3665–3676 (2010). · DOI
  33. Hirokawa, Y., Arnold, M., Nakajima, H., Zalcberg, J. & Maruta, H. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol. Ther. 4, 956–960 (2005). · DOI
  34. Scott, S. M., Brown, M. & Come, S. E. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer. Expert. Opin. Drug. Saf. 10, 819–826 (2011). · DOI
  35. Hu, X. F. et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int. J. Cancer 55, 873–876 (1993). · DOI
  36. Veronesi, U. et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann. Oncol. 17, 1065–1071 (2006). · DOI · Paper page
  37. Connolly, R., Nguyen, N. K. & Sukumar, S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin. Cancer Res. 19, 1651–1659 (2013). · DOI · Paper page
  38. Eriksson, H. et al. Quantitative membrane proteomics applying narrow range peptide isoelectric focusing for studies of small cell lung cancer resistance mechanisms. Proteomics 8, 3008–3018 (2008). · DOI · Paper page
  39. Sanchez, B. C. et al. Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF. Eur. J. Cancer 46, 1580–1587 (2010). · DOI
  40. Linderholm, B. K., Hellborg, H., Johansson, U., Skoog, L. & Lehtio, J. Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer. Breast. Cancer Res. Treat. 125, 457–465 (2011). · doi:10.1007/s10549-010-1252-x

Cited by

Metadata

Authors
Johansson, H. J., Sanchez, B. C., Mundt, F., Forshed, J., Kovacs, A., Panizza, E., Hultin-Rosenberg, L., Lundgren, B., Martens, U., Máthé, G., Yakhini, Z., Helou, K., Krawiec, K., Kanter, L., Hjerpe, A., Stål, O., Linderholm, B. K., & Lehtiö, J.
Venue
Nature Communications
Published
2013-07-19
Volume
4
Issue
1
Pages
2175-2175
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2027444207
Cited by
60
References
5
FWCI
5.26
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.